Abstract: The invention provides an optical connector assembly for arrangement on a first optical printed circuit board and for connecting the first optical printed circuit board to a second optical device on a second electro optical printed circuit board, the connector assembly comprising: an electrical connector; and an optical connector; the optical connector being arranged in a housing that is fixed relative to the electrical connector, the optical connector being movably mounted in the housing so that the optical connector can move relative to the electrical connection, such that when electrical connection is made, the optical connector can still move with at least three degrees of freedom.

Abstract: The invention provides an optical connector assembly for arrangement on a first optical printed circuit board and for connecting the first optical printed circuit board to a second optical device on a second electro optical printed circuit board, the connector assembly comprising: an electrical connector; and an optical connector; the optical connector being arranged in a housing that is fixed relative to the electrical connector, the optical connector being movably mounted in the housing so that the optical connector can move relative to the electrical connection, such that when electrical connection is made, the optical connector can still move with at least three degrees of freedom.

Abstract: A class of substituted phenylpyrimidine compounds are disclosed which are potent inhibitors of the excitatory amino acid, glutamate. Such compounds are useful in the treatment or prevention of a range of CNS disorders including cerebral ischaemic damage and epilepsy.

Abstract: A class of substituted phenylpyrimidine compounds are disclosed which are potent inhibitors of the excitatory amino acid, glutamate. Such compounds are useful in the treatment or prevention of a range of CNS disorders including cerebral ischaemic damage and epilepsy.

Abstract: A class of substituted phenylpyrimidine compounds are disclosed which are potent inhibitors of the excitatory amino acid, glutamate. Such compounds are useful in the treatment or prevention of a range of CNS disorders including cerebral ischaemic damage and epilepsy.

Abstract: A class of substituted phenylpyrimidine compounds are disclosed which are potent inhibitors of the excitatory amino acid, glutamate. Such compounds are useful in the treatment or prevention of a range of CNS disorders including cerebral ischaemic damage and epilepsy.

Abstract: A class of substituted phenylpyrimidine compounds are disclosed which are potent inhibitors of the excitatory amino acid, glutamate. Such compounds are useful in the treatment or prevention of a range of CNS disorders including cerebral ischaemic damage and epilepsy.

Abstract: A class of substituted phenylpyrimidine compounds are disclosed which are potent inhibitors of the excitatory amino acid, glutamate. Such compounds are useful in the treatment or prevention of a range of CNS disorders including cerebral ischaemic damage and epilepsy.

Abstract: Compounds of Formula I are novel and useful as cardiovascular agents, particularly anti-arrhythmic agents: ##STR1## or the 5-imino-tautomer thereof or a salt of either, wherein R.sup.1 is C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl or C.sub.3-10 cycloalkyl, any of which is optionally substituted, and R.sup.2 to R.sup.6 are independently selected from hydrogen, halogen atom, C.sub.1-6 alkyl, alkenyl or alkynyl (all optionally substituted by one or more of halogen, hydroxy and aryl, amino, mono- or di-substituted amino, alkoxy (optionally substituted by one or more of halogen, hydroxy and aryl), alkenyloxy, aryl, acyloxy, cyano, nitro, aryl and alkylthio groups or any adjacent two of R.sup.2 to R.sup.6 are linked to form a (--CH.dbd.CH--CH.dbd.CH--) group.

Abstract: The present invention provides compounds of the formula (III): ##STR1## or an acid addition salt thereof, wherein R.sup.6 is chlorine, bromine, iodine, C.sub.1-4 alkyl or trifluoromethyl, or R.sup.6 and R.sup.7 from a --CH.dbd.CH--CH.dbd.CH-- group optionally substituted by a halogen atom or a C.sub.1-4 alkyl or trifluoromethyl group, R.sup.8 is hydrogen, bromine, iodine, C.sub.1-4 alkyl or trifluoromethyl, R.sup.9 is hydrogen, halogen, C.sub.1-4 alkyl or trifluoromethyl, R.sup.10 is hydrogen, methyl or fluorine and R.sup.11 is amino, C.sub.1-10 acylamino or di-substituted aminomethyleneamino provided that, at most, only two of R.sup.7 -R.sup.10 are other than hydrogen and that R.sup.7 -R.sup.10 are not all hydrogen when R.sup.6 is chlorine. Also provided are pharmaceutical compositions containing compounds of the formula (III), the first medical use of compounds of the formula (III), a process for preparing such compounds and intermediates through which this process proceeds.

Abstract: The present invention provides compounds of the formula (III): ##STR1## or an acid addition salt thereof, wherein R.sup.6, R.sup.7, R.sup.9 and R.sup.10 are each hydrogen, halogen, C.sub.1-4 alkyl or trifluoromethyl and R.sup.8 is chlorine or R.sup.7 and R.sup.8 are linked to form a --CH.dbd.CH--CH.dbd.CH-- group when one of R.sup.6 and R.sup.10 is other than hydrogen provided that when R.sup.8 is chlorine R.sup.6, R.sup.7, R.sup.9 and R.sup.10 are not all hydrogen atoms and that any one of R.sup.6, R.sup.7, R.sup.9 and R.sup.10 is not chlorine when the other three groups are hydrogen. Also provided are pharmaceutical compositions containing compounds of the formula (III), the first medical use of compounds of the formula (III), a process for preparing such compounds and intermediates through which this process proceeds.

Abstract: The present invention provides compounds of the formula (III): ##STR1## or an acid addition salt thereof, wherein R.sup.6 is chlorine, bromine, iodine, C.sub.1-4 alkyl or trifluoromethyl, or R.sup.6 and R.sup.7 form a --CH.dbd.CH--CH.dbd.CH--group optionally substituted by a halogen atom or a C.sub.1-4 alkyl or trifluoromethyl group, R.sup.8 is hydrogen, bromine, iodine, C.sub.1-4 alkyl or trifluoromethyl, R.sup.9 is hydrogen, halogen, C.sub.1-4 alkyl or trifluoromethyl, R.sup.10 is hydrogen, methyl or fluorine and R.sup.11 is amino, C.sub.1-10 acylamino or di-substituted aminomethyleneamino provided that, at most, only two of R.sup.7 -R.sup.10 are other than hydrogen and that R.sup.7 -R.sup.10 are not all hydrogen when R.sup.6 is chlorine. Also provided are pharmaceutical compositions containing compounds of the formula (III), the first medical use of compounds of the formula (III), a process for preparing such compounds and intermediates through which this process proceeds.

Abstract: The medical use of compounds of the formula (III): ##STR1## or pharmaceutically acceptable and addition salts thereof, wherein R.sup.6 is a hydrogen atom, R.sup.5 is a chlorine atom and R.sup.7 is a hydrogen or chlorine atom or R.sup.7 is a chlorine atom, R.sup.5 is a hydrogen atom and R.sup.6 is a chlorine atom, particularly for the treatment of CNS disorders, is disclosed. Solid pharmaceutical compositions are also described.